1. Home
  2. HNNA vs SAVA Comparison

HNNA vs SAVA Comparison

Compare HNNA & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HNNA
  • SAVA
  • Stock Information
  • Founded
  • HNNA 1989
  • SAVA 1998
  • Country
  • HNNA United States
  • SAVA United States
  • Employees
  • HNNA N/A
  • SAVA 30
  • Industry
  • HNNA Investment Managers
  • SAVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HNNA Finance
  • SAVA Health Care
  • Exchange
  • HNNA Nasdaq
  • SAVA Nasdaq
  • Market Cap
  • HNNA 82.4M
  • SAVA 70.5M
  • IPO Year
  • HNNA N/A
  • SAVA N/A
  • Fundamental
  • Price
  • HNNA $10.99
  • SAVA $1.57
  • Analyst Decision
  • HNNA
  • SAVA Buy
  • Analyst Count
  • HNNA 0
  • SAVA 3
  • Target Price
  • HNNA N/A
  • SAVA $54.50
  • AVG Volume (30 Days)
  • HNNA 23.5K
  • SAVA 1.2M
  • Earning Date
  • HNNA 05-07-2025
  • SAVA 05-09-2025
  • Dividend Yield
  • HNNA 5.00%
  • SAVA N/A
  • EPS Growth
  • HNNA 75.66
  • SAVA N/A
  • EPS
  • HNNA 1.12
  • SAVA N/A
  • Revenue
  • HNNA $33,210,000.00
  • SAVA N/A
  • Revenue This Year
  • HNNA N/A
  • SAVA N/A
  • Revenue Next Year
  • HNNA N/A
  • SAVA N/A
  • P/E Ratio
  • HNNA $9.24
  • SAVA N/A
  • Revenue Growth
  • HNNA 38.27
  • SAVA N/A
  • 52 Week Low
  • HNNA $6.60
  • SAVA $1.15
  • 52 Week High
  • HNNA $13.88
  • SAVA $42.20
  • Technical
  • Relative Strength Index (RSI)
  • HNNA 60.98
  • SAVA 45.15
  • Support Level
  • HNNA $9.46
  • SAVA $1.37
  • Resistance Level
  • HNNA $10.78
  • SAVA $1.73
  • Average True Range (ATR)
  • HNNA 0.73
  • SAVA 0.13
  • MACD
  • HNNA 0.19
  • SAVA 0.08
  • Stochastic Oscillator
  • HNNA 99.61
  • SAVA 76.72

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: